Participant flow30

How many started, completed or left each group, period by period.

1 to 20 of 30

Period	Milestone	Group	Participants
Overall Study	STARTED	VPR 4 mg	62
Overall Study	STARTED	VPR 2 mg	61
Overall Study	STARTED	VPR 1 mg	63
Overall Study	STARTED	VPR 0.5 mg	62
Overall Study	STARTED	Placebo	61
Overall Study	Treated	VPR 4 mg	60
Overall Study	Treated	VPR 2 mg	61
Overall Study	Treated	VPR 1 mg	61
Overall Study	Treated	VPR 0.5 mg	60
Overall Study	Treated	Placebo	58
Overall Study	Completed Treatment	VPR 4 mg	57
Overall Study	Completed Treatment	VPR 2 mg	60
Overall Study	Completed Treatment	VPR 1 mg	61
Overall Study	Completed Treatment	VPR 0.5 mg	56
Overall Study	Completed Treatment	Placebo	52
Overall Study	Completed Follow-up	VPR 4 mg	54
Overall Study	Completed Follow-up	VPR 2 mg	47
Overall Study	Completed Follow-up	VPR 1 mg	56
Overall Study	Completed Follow-up	VPR 0.5 mg	42
Overall Study	Completed Follow-up	Placebo	44

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02131662/flow